Patrizia Dell’Orto

机构：European School of Oncology, Istituti di Ricovero e Cura a Carattere Scientifico, European Institute of Oncology · ORCID：0000-0001-9166-0829

发表论文 127 篇 · 总被引 4630 次 · h-index 35

代表论文

• Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT (2024 · Journal of Clinical Oncology · 被引 41)
• HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial (2024 · Journal of Clinical Investigation · 被引 30)
• Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer (2024 · JAMA Oncology · 被引 12)
• 109O Adjuvant endocrine therapy for premenopausal invasive lobular carcinoma (ILC): Results from SOFT and TEXT phase III studies (2024 · ESMO Open · 被引 5)
• Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials (2025 · JCO Precision Oncology · 被引 3)
• Abstract PS09-02: Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer (2024 · Cancer Research · 被引 3)